Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:06:43.482Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:06:43.482Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Eocene Ltd.
Market Cap
$3.50M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Eocene Ltd. (EOCN) | $3.50M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
